Breaking AI & Tech News Analyzed

GSK has revealed promising early results for its treatment for gynaecological cancers, Mocertatug Rezetecan (Mo-Rez), as its chief executive, Luke Miels, seeks to speed up drug development at the group.The company reported that in an early-stage trial, Mo-Rez shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharma in late 2023, and has trialled it in 224 patients around the world, including the UK, over the past year. Few patients needed to stop treatment because of side-effects, the most common being nausea. It is administered every three weeks via intravenous infusion.Combined with data from a separate, intermediate trial in China, these results give GSK the confidence to go straight to late-stage trials, with five clinical studies planned globally in the next few months, including on patients in the UK.Presenting the results at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Puerto Rico, Hesham Abdullah, GSK’s global head of cancer research and development, said: “Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez we now have compelling evidence of a promising clinical profile.”Endometrial cancer affects 1.6 million women globally, with 417,000 new cases each year. Ovarian cancer affects 843,000 people, with 240,000 new cases annually.Abdullah described Mo-Rez as a “key asset” in the company’s growing cancer portfolio, expected to be a blockbuster drug with peak annual sales of more than £2bn, which GSK hopes will help it achieve its 2031 sales target of £40bn.

The United States has revoked the permanent residency of two women identified as relatives of the late Quds Force commander Qassem Soleimani, the former head of Iran’s Islamic Revolutionary Guard Corps foreign arm.According to a State Department statement released on Saturday, Hamideh Soleimani Afshar—Soleimani’s niece—and her daughter were arrested on Friday night and are now in the custody of Immigration and Customs Enforcement (ICE), which is seeking their removal from the country.The decision has sparked a debate over the limits of free‑speech protections in the United States and whether family members should be penalised for the actions or affiliations of their relatives.In its release, the State Department described Afshar as “an outspoken supporter of the totalitarian, terrorist regime in Iran,” adding that such rhetoric would not be tolerated under the Trump administration. The statement read: “The Trump Administration will not allow our country to become a home for foreign nationals who support anti‑American terrorist regimes.”Iranian media, however, quoted Afshar’s daughter, Zeinab Soleimani, who denied any connection to the late Quds Force leader, stating, “The individuals arrested in the United States have no connection whatsoever to martyr Soleimani, and the claim made by the US State Department is false.”The arrests occur at the five‑week mark of the U.S.‑Israel war on Iran, which began on February 28, 2026.This is the second known instance this month that the Trump administration has stripped legal immigration status from individuals allegedly linked to senior Iranian figures.Secretary of State Marco Rubio took to social media to claim credit for the action, writing, “This week, I terminated both Afshar and her daughter’s legal status.” He added that Afshar had “celebrated attacks on Americans and referred to our country as the ‘Great Satan.’”The State Department also highlighted Afshar’s “lavish lifestyle” in Los Angeles and noted that her husband has been barred from entering the United States.Similar pressure was applied earlier this month to Fatemeh Ardeshir‑Larijani, the daughter of the late Iranian official Ali Larijani. Both she and her husband, Seyed Kalantar Motamedi, had their U.S. immigration status revoked and were prohibited from re‑entering the country. Larijani, a former head of Iran’s Supreme National Security Council, was killed in an Israeli airstrike on March 17.The moves reflect growing influence from conservative politicians and activists demanding the expulsion of individuals with familial ties to Iran’s leadership.Far‑right influencer and Trump ally Laura Loomer claimed she had reported Afshar to the State Department and thanked Rubio, calling the removal a “big scalp.” An online petition on Change.org, launched two months ago, had already gathered more than 4,000 signatures calling for Afshar’s deportation.Ardeshir‑Larijani, who previously worked in oncology at Emory University’s School of Medicine, became a target of protests after Iran’s crackdown on anti‑government demonstrators in December and January. A separate Change.org petition demanding her deportation amassed 157,017 signatures by Saturday.The petition emphasized her familial links to Iran’s Supreme Leader Ali Khamenei, who was killed on the first day of the war, arguing that while she lives peacefully in the U.S., “countless young Iranians are dying in Iran due to the policies and decisions made by Ali Khamenei and his inner circle, including her father.”U.S. Congressman Earl “Buddy” Carter of Georgia echoed the call, urging that Ardeshir‑Larijani’s medical license be revoked. He wrote, “America’s medical institutions must not serve as a safe harbor for individuals connected by blood and loyalty to regimes that openly call for the death of Americans.”According to Emory’s student newspaper, The Emory Wheel, Ardeshir‑Larijani was no longer employed by the university as of January.